These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30043475)

  • 21. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
    Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
    Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
    Dunleavy K
    Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
    Drexler HG; Eberth S; Nagel S; MacLeod RA
    Leuk Lymphoma; 2016 May; 57(5):1015-20. PubMed ID: 26727417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
    Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
    Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
    Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S; Bellamy WT; Gokden M
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
    Rosenthal A; Younes A
    Blood Rev; 2017 Mar; 31(2):37-42. PubMed ID: 27717585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytopathology of "double-hit" non-Hodgkin lymphoma.
    Elkins CT; Wakely PE
    Cancer Cytopathol; 2011 Aug; 119(4):263-71. PubMed ID: 21560252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Mediastinal Large B-Cell Lymphoma With Translocations Involving BCL6 and MYC (Double-Hit Lymphoma).
    Campuzano-Zuluaga G; Ortiz D; Peng JH; Francis Ikpatt O; Fan YS; Barredo JC; Vega F; Chapman JR
    Am J Clin Pathol; 2016 May; 145(5):710-6. PubMed ID: 27124935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the Detection of MYC and BCL2 (and BCL6) Rearrangements in Large B-Cell Lymphomas: Updates Amid the New WHO Classification of Lymphoid Neoplasms.
    de Lima Guido LP; Chapman J; Cassidy DP
    Am J Clin Pathol; 2023 Jul; 160(1):41-48. PubMed ID: 36881639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
    Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-Hit and Triple-Hit Follicular Lymphoma.
    Ziemba JB; Wolf Z; Weinstock M; Asakrah S
    Am J Clin Pathol; 2020 Apr; 153(5):672-685. PubMed ID: 32112707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Successful treatment with dose-adjusted EPOCH-R for triple-hit lymphoma having BCL2, BCL6 and MYC translocations].
    Hashimoto A; Fujimi A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Matsumoto T; Shibata T; Hamaguchi K; Kamihara Y; Iwasaki S; Kato J
    Rinsho Ketsueki; 2015 Jul; 56(7):905-10. PubMed ID: 26256929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
    Petrich AM; Nabhan C; Smith SM
    Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
    Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.